Cat. No.: DAB-0011754
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr645 of human annexin A6 protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ANXA6 |
| UniProt No. | P08133 |
| Gene ID | 309 |
| Gene Description | Annexin A6 belongs to the highly conserved annexin family of proteins characterized by their calcium -dependent binding to phospholipids. The protein is highly expressed in most tissues and is predominantly located at the plasma membrane and the endosomal compartment, where it regulates cell migration and endosome trafficking by organizing membrane domains, interacting with signaling complexes, and forming transient membrane-actin interactions upon Ca2+ stimulation. It also mediates intracellular cholesterol homeostasis. Annexin A6 is frequently upregulated in extracellular vesicles of the tumor microenvironment after chemotherapy or tyrosine kinase inhibitor treatment. These EVs have been shown to promote resistance and metastasis in multiple cancer types, such as lung cancer, breast cancer, and pancreatic duct adenocarcinoma. Annexin A6, in these EVs, enhances the stability of membrane-associated RTKs, such as EGFR, and promotes cancer cell motility, stemness, and autophagy. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
